Vertex Pharmaceuticals (CHIX:VX1D) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VX1D Vertex Pharmaceuticals Inc CHIX:VX1D
87 GF Score
Price €322.40
GF Value €344.13
! 4 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vertex Pharmaceuticals  (CHIX:VX1d) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.19 17.86 20.54 16.56 15.60

Vertex Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.55 13.93 15.60 14.62 15.55

CHIX:VX1D vs REGN, RVMD, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


CHIX:VX1D
87GF Score
Vertex Pharmaceuticals Inc CHIX:VX1D
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Vertex Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=11.339/333.9520*333.9520
=11.339

Current CPI (Jun. 2026) = 333.9520.

Vertex Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.505 241.428 2.082
201612 1.774 241.432 2.454
201703 2.687 243.801 3.681
201706 1.925 244.955 2.624
201709 1.938 246.819 2.622
201712 2.146 246.524 2.907
201803 2.010 249.554 2.690
201806 2.490 251.989 3.300
201809 2.588 252.439 3.424
201812 2.944 251.233 3.913
201903 2.920 254.202 3.836
201906 3.206 256.143 4.180
201909 3.311 256.759 4.306
201912 4.850 256.974 6.303
202003 5.203 258.115 6.732
202006 5.139 257.797 6.657
202009 4.945 260.280 6.345
202012 5.117 260.474 6.560
202103 5.530 264.877 6.972
202106 5.703 271.696 7.010
202109 6.494 274.310 7.906
202112 7.140 278.802 8.552
202203 7.385 287.504 8.578
202206 8.031 296.311 9.051
202209 9.085 296.808 10.222
202212 8.351 296.797 9.396
202303 8.521 301.836 9.428
202306 8.837 305.109 9.672
202309 8.930 307.789 9.689
202312 8.852 306.746 9.637
202403 9.480 312.332 10.136
202406 9.523 314.175 10.122
202409 9.569 315.301 10.135
202412 10.808 315.605 11.436
202503 9.875 319.799 10.312
202506 9.928 322.561 10.279
202509 10.175 324.800 10.462
202512 10.633 324.054 10.958
202603 10.081 330.213 10.195
202606 11.339 333.952 11.339

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Vertex Pharmaceuticals (CHIX:VX1D) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €322.40 is trading 6.3% below its estimated GF Value™ of €344.13.

Key valuation signals for CHIX:VX1D:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €344.13 vs. price of €322.40 (6.3% below fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the CHIX:VX1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
87GF Score

Get the complete analysis for CHIX:VX1D

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€322.40
Price
€344.13
GF Value